moonlight

9.7.26

Meet SK Hynix, the Trillion-Dollar South Korean Chipmaker Debuting on U.S. Markets

**The company you've never heard of is the hidden engine behind the AI revolution. On Friday, it lands on the Nasdaq—and it could be the biggest semiconductor story of the decade.**

---

## Introduction: The AI Memory King Comes to America

There's a company that makes the memory chips that power every Nvidia GPU in every AI data center on the planet. It controls nearly 60% of the market for high-bandwidth memory (HBM)—the specialized chips that sit alongside Nvidia's processors and feed them data at lightning speed. Its operating margins exceed 70%, surpassing even Nvidia's legendary profitability. Its market cap has more than tripled in 2026 to over $1 trillion.

And until this week, most American investors couldn't easily buy its stock.

That changes on Friday, July 10, 2026, when SK Hynix begins trading on the Nasdaq under the ticker **SKHY** (initially SKHYV on a when-issued basis, switching to SKHY on July 13). The company is raising approximately **$28–29 billion** through the sale of American Depositary Receipts (ADRs), making it the **second-largest share sale in history**—behind only SpaceX's $85.7 billion IPO.

For anyone trying to invest in the AI boom, this is a name worth understanding. Here's everything you need to know.

---

## From Near-Bankruptcy to Trillion-Dollar AI Powerhouse

### A 40-Year Journey

SK Hynix's story is one of the most dramatic turnarounds in corporate history. The company was founded in **1983** as Hyundai Electronics, an offshoot of the South Korean auto giant. For decades, it was a struggling memory chip maker, lurching from crisis to crisis as the semiconductor industry's brutal boom-and-bust cycles threatened its survival.

In the early 2000s, collapsing memory prices pushed the company toward bankruptcy. It survived as a creditor-controlled "zombie" enterprise following the Asian financial crisis of 1997–1998 and the DRAM oversupply that followed.

The turning point came in **2012**, when SK Group acquired Hynix Semiconductor in a deal widely viewed at the time as risky. The new owners backed a long-term bet on a then-obscure technology called **high-bandwidth memory (HBM)**—a bet that would take more than a decade to pay off.

### The HBM Gamble

In 2009, SK Hynix foresaw an increasing demand for high-performance memory and turned its attention to TSV (through-silicon via) technology. The company spent more than 15 years researching and developing HBM, often at the expense of other product lines.

That gamble started paying off in 2023, when the AI boom turned HBM from a niche product into the most sought-after memory technology on the planet. In March 2025, SK Hynix became the **first in the world to supply samples of 12-layer HBM4**, the sixth generation of HBM. Today, it is Nvidia's primary HBM supplier, providing an estimated **50–70% of Nvidia's HBM4 requirements**.

### The Valuation Explosion

The results speak for themselves. SK Hynix shares have surged more than **280% in 2026 alone**. The company's market capitalization has surpassed **$1 trillion**, making it one of the most valuable semiconductor companies in the world.

The company's **Q1 2026 financial results** were nothing short of staggering:

- **Revenue**: 52.5763 trillion won ($34.3 billion)

- **Operating profit**: 37.6103 trillion won ($24.5 billion)

- **Net profit**: 40.3459 trillion won ($27.2 billion)

- **Operating margin**: 72% (an all-time high)

To put that in perspective: SK Hynix's **net profit in a single quarter** surpassed its **entire revenue for fiscal year 2023**. The company is projecting 2026 net profit of **221 trillion won ($144 billion)** and revenue of **355 trillion won ($231 billion)**—representing year-over-year increases of **415% and 265%**, respectively.

---

## Why SK Hynix Matters: The HBM Monopoly

### What Is HBM?

High-bandwidth memory (HBM) is the specialized memory that sits alongside Nvidia's GPUs in AI data centers. Unlike traditional DRAM, HBM is stacked vertically—like a skyscraper instead of a ranch house—allowing it to move data much faster while using less power.

Every time you use ChatGPT, generate an image with Midjourney, or interact with any large AI model, you're relying on HBM. The memory feeds data to the GPU at the speed required for AI inference and training. Without HBM, the AI revolution would grind to a halt.

### Market Dominance

SK Hynix holds approximately **57–60% of the global HBM market**. Its closest competitors are Samsung (around 22%) and Micron (around 21%).

The company's **operating margin of 72%** in Q1 2026 reflects this dominance. When you control the most critical component in the world's fastest-growing technology sector, pricing power follows.

### The Nvidia Partnership

In June 2026, Nvidia and SK Hynix announced a **multi-year technology partnership** covering multiple product generations and extending through **2030**. The agreement locks in HBM supply for Nvidia's Vera Rubin AI supercomputers, Vera CPUs, RTX Spark-powered PCs, and more.

Nvidia CEO Jensen Huang has warned that the memory shortage could "last for years". For SK Hynix, that means structural demand growth for the full duration of the AI cycle.

---

## The Nasdaq Listing: What Investors Need to Know

### The Deal Details

- **Ticker**: SKHY (initially SKHYV on July 10; switching to SKHY on July 13)

- **Exchange**: Nasdaq Global Select Market

- **ADRs Offered**: 177.9 million ADRs (representing 17.79 million common shares)

- **ADR Ratio**: 10 ADRs = 1 common share

- **Target Raise**: $28–29 billion

- **Pricing**: $149–$166 per ADR

- **Trading Starts**: July 10, 2026 (when-issued); regular trading begins July 13

- **Rank**: Second-largest share sale in history, behind only SpaceX

### Oversubscribed by 700%

The offering has been **more than seven times oversubscribed**. Anchor investors—including **Baillie Gifford, Coatue Management, and Situational Awareness Partners**—have collectively indicated interest totaling up to **$7 billion**.

Investor demand spans "global long-only funds, technology-focused funds, sovereign wealth funds and Asia-focused global investors," according to Bloomberg.

### Why a U.S. Listing Matters

SK Hynix is already one of the world's most valuable semiconductor companies. But its Korea-only listing has limited access for many global investors. As one analyst put it: "SK Hynix is one of the clearest ways to gain exposure to AI-driven memory demand, but its Korea-only listing has limited access for many global investors".

The Nasdaq listing solves that problem. It also addresses the **"Korea discount"** —the persistent valuation gap between Korean-listed companies and their U.S. peers. HSBC analysts have applied a 20% premium to SK Hynix's valuation to reflect the ADR listing, forecasting it will help the company "catch up with US-based Micron Technology in valuation terms".

As SK Hynix said in its filing: "We expect to elevate our status as a global company by broadening our touchpoints in the United States, the epicenter of AI technological innovation".

---

## The Competitive Landscape: Samsung and Micron

### Samsung: The Sleeping Giant

Samsung Electronics, SK Hynix's longtime rival, has been working to close the HBM gap. The company is leading HBM4 validation due to process improvements enhancing stability. However, SK Hynix retains the volume leadership despite some re-sampling delays.

The competition is intensifying. TrendForce reports that HBM4 validation timelines are diverging, with Samsung gaining ground as SK Hynix faces qualification delays. But for now, SK Hynix remains the dominant player.

### Micron: The American Challenger

Micron Technology, the U.S.-based memory chipmaker, has been aggressively investing in its own HBM roadmap. The company's Q3 2026 earnings—which saw revenue more than quadruple—reinforced expectations that the AI memory market remains supply-constrained.

Micron has traded at an average **35% premium to SK Hynix** over the past 13 years, driven by "better access to US investors, a more shareholder-friendly policy, and higher beta supported by a smaller earnings base". The Nasdaq listing is expected to narrow that gap.

---

## The Risks: What Could Go Wrong

### The Memory Cycle

Semiconductors are cyclical. The current boom is driven by AI infrastructure spending, which shows no signs of slowing—but it will eventually normalize. UBS has forecast that the DRAM industry will face a supply shortage until at least the second quarter of 2028. After that, increased capacity could pressure prices.

### Competition

Samsung is investing heavily to close the HBM gap. Micron is expanding capacity. If competitors catch up, SK Hynix's market share and pricing power could erode.

### Geopolitical Risk

SK Hynix is a South Korean company operating in a region of escalating geopolitical tension. U.S.-China technology restrictions, potential disruptions to the Taiwan Strait, and the ongoing U.S.-Iran conflict all pose risks to the global semiconductor supply chain.

### Valuation

SK Hynix shares have surged more than 700% over the past 12 months. Even after a roughly 20% pullback from its June 2026 peak, the stock remains at historically elevated levels. The Nasdaq listing could provide a short-term boost, but long-term investors should consider whether the current valuation fully reflects the company's growth trajectory.

---

## Frequently Asked Questions

### Q: What does SK Hynix do?

A: SK Hynix is the world's leading manufacturer of high-bandwidth memory (HBM) chips, which are essential components in Nvidia's AI GPUs. The company also produces DRAM and NAND flash memory for a wide range of applications.

### Q: When does SK Hynix start trading on the Nasdaq?

A: SK Hynix begins trading on the Nasdaq on **Friday, July 10, 2026**, under the ticker **SKHY** (initially SKHYV on a when-issued basis; switching to SKHY on July 13).

### Q: How much is SK Hynix raising?

A: The company is raising approximately **$28–29 billion**, making it the second-largest share sale in history, behind only SpaceX.

### Q: What is the ADR ratio?

A: **10 ADRs represent one common share** of SK Hynix.

### Q: How is SK Hynix's business performing?

A: In Q1 2026, SK Hynix reported **52.6 trillion won in revenue** ($34.3 billion), **37.6 trillion won in operating profit** ($24.5 billion), and an **operating margin of 72%**. The company is projecting 2026 net profit of **$144 billion** and revenue of **$231 billion**.

### Q: How does SK Hynix compare to Samsung and Micron?

A: SK Hynix holds approximately **57–60% of the global HBM market**, compared to Samsung's roughly 22% and Micron's roughly 21%.

### Q: What is SK Hynix's relationship with Nvidia?

A: SK Hynix is Nvidia's **primary HBM supplier**, providing an estimated **50–70% of Nvidia's HBM4 requirements**. The companies have a multi-year partnership extending through **2030**.

### Q: Why is SK Hynix listing in the U.S.?

A: The listing broadens SK Hynix's investor base, provides access to U.S.-only institutional mandates, and helps narrow the valuation gap with U.S. peers like Micron.

---

## Conclusion: The AI Memory King Comes to Wall Street

SK Hynix's Nasdaq debut is a watershed moment for the AI semiconductor industry. The company that was nearly bankrupt two decades ago now controls the most critical component in the world's fastest-growing technology sector. Its 72% operating margins, $1 trillion market cap, and dominant HBM position make it one of the most important companies you've never heard of.

**Here's what we know for certain:**

**The timing is right.** The AI boom is accelerating, and the memory shortage shows no signs of easing. UBS forecasts supply constraints through at least Q2 2028.

**The valuation gap is closing.** The Nasdaq listing is expected to narrow the discount at which SK Hynix has historically traded relative to U.S. peers.

**The demand is insatiable.** With Nvidia locked into a multi-year partnership and hyperscalers continuing to ramp up AI infrastructure spending, SK Hynix's growth trajectory appears secure for the foreseeable future.

**The risks are real.** Competition from Samsung and Micron, the cyclical nature of the semiconductor industry, and geopolitical tensions all pose potential headwinds.

For American investors, the question isn't whether SK Hynix is a compelling AI play—it's whether the current valuation reflects the company's full potential, or whether there's still room to run.

As one analyst put it: "What is clear is that SK is definitely the top notch player in HBM. And it is better in cost of manufacturing. So its operating margin is the best. So it has the best product, lowest cost. What do you need else?"

The AI memory king has arrived on Wall Street. Now it's up to investors to decide what it's worth.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, stock prices, and company performance are subject to rapid change. Past performance is not indicative of future results. You should consult with a qualified financial advisor before making any investment decisions.

--Read more from moonlight-

*Published: July 9, 2026*

--Read more -

**Tags:** SK Hynix, SKHY stock, Nasdaq IPO, HBM memory, AI semiconductors, Nvidia supplier, South Korean chipmaker, semiconductor stocks, AI infrastructure, high-bandwidth memory, SK Hynix IPO, chip stocks, AI memory, semiconductor investing, SK Hynix ADR, Nasdaq listing, AI boom, memory chips, tech IPO, semiconductor industry

Nasdaq Rises as Chip Stocks Rebound and Trump Flips the Script on Iran

## The Dow shed 576 points on Wednesday. Then Trump said Iran called to make a deal. Here's how traders navigated the whiplash — and why semiconductor stocks are leading the recovery.

8.7.26

U.S. Stocks Fall After Trump Says Iran Ceasefire Is Over for Him

## The Dow plunges 800 points, oil surges 8%, and the geopolitical risk premium that investors thought was gone comes roaring back.

---

### Introduction: The "Peace Dividend" Lasted Just Three Weeks

On June 17, 2026, the world breathed a collective sigh of relief. The U.S. and Iran signed a memorandum of understanding, bringing a fragile ceasefire to a war that had sent oil prices soaring past $120 a barrel and threatened to destabilize the global economy. Investors celebrated. Oil prices plunged back to prewar levels. The stock market rallied.

That peace dividend lasted exactly 21 days.

On Wednesday, July 8, 2026, President Donald Trump declared the ceasefire "over," signaling a dramatic escalation in the conflict and sending shockwaves through global markets. "I think it's over. I don't want to deal with them anymore. They're scum," Trump said at the NATO summit in Ankara, Turkey. He later told reporters the U.S. would strike again, saying "we're going to hit them hard tonight".

The Dow Jones Industrial Average plunged nearly **800 points**. Oil surged more than **8%**. And the geopolitical risk premium that investors had so eagerly discounted just weeks ago came roaring back.

---

### The Numbers That Matter: A Market in Panic

Let's start with the damage. As of midday trading on Wednesday, July 8:

|-------|-------|--------|----------|

| **Dow Jones** | ~52,126 | **-831 points** | **-1.6%** |

| **S&P 500** | ~7,443 | **-60 points** | **-1.0%** |

| **Nasdaq** | ~25,649 | **-169 points** | **-1.0%** |

Losses were broad-based across all major indexes, with the Nasdaq Composite off 0.6%, the S&P 500 down 0.7%, and the Dow Jones Industrial Average shedding 709 points, equivalent to a 1.3% decline.

The worry is that a continuation of the war will block the Strait of Hormuz and keep oil tankers bottled up in the Persian Gulf instead of delivering crude to customers worldwide. That could worsen inflation—which economists had expected to ease with falling oil prices—and in turn force the Federal Reserve to raise interest rates.

---

### The Ceasefire Collapse: What Happened?

The collapse didn't happen overnight—but it happened fast.

**The backstory:** On June 17, the U.S. and Iran signed a 14-page memorandum of understanding aimed at extending the ceasefire and ending the conflict "on all fronts". The agreement included provisions for Iran to resume oil exports, the reopening of the Strait of Hormuz, and a 60-day negotiation window toward a permanent truce. Investors treated the deal as a geopolitical breakthrough.

**The unraveling:** The truce had been "on shaky ground for weeks," according to the New York Times. The two sides traded new attacks overnight, and Trump's declaration that the deal was "over" was the clearest sign yet that the temporary ceasefire had collapsed.

**The trigger:** Trump's remarks followed U.S. strikes against Iran on Tuesday, carried out in response to attacks on three commercial vessels in the Strait of Hormuz. Iran had targeted U.S. military sites in Bahrain and Kuwait, and the U.S. responded forcefully.

**NATO's role:** NATO Secretary General Mark Rutte said at the summit that the American strikes were "absolutely necessary." "When you have a ceasefire and Iran is basically violating the ceasefire—we see what happened yesterday with ships being attacked—I think it is totally crucial that the U.S. forcefully reacts," Rutte said.

**The human toll:** Trump was characteristically blunt. "For me, I think it's over," he told reporters, adding that continuing to deal with Iran was "just a waste of time. They're liars". He later said the U.S. was preparing for another night of strikes.

---

### Why the Market Reaction Wasn't Worse

Given the gravity of Trump's comments, some analysts noted that the market reaction could have been far more severe. "All things considered, markets are taking the latest escalation in Middle East in stride," CNBC reported. Comments such as those would have sparked a "massive decline in equities and a surge in oil prices a few months ago".

Several traders noted one reason for the muted reaction: **neither side wants to prolong the war**. "The situation has not materially changed with neither US / Iran showing a desire for an extended conflict," JPMorgan's trading desk wrote. Indeed, Trump also said negotiations to end the war can continue.

Adam Crisafulli of Vital Knowledge offered a similar assessment: "While the current détente is certainly under strain, we continue to think the White House is extremely reluctant to escalate militarily and fully return to hostilities and therefore, a deal remains much more likely than not (unless Trump plans on putting troops on the ground, which he clearly doesn't want to do, a negotiated settlement is the only way to extract himself from a war he regrets starting)".

However, the latest events cloud the outlook for a resolution to the conflict. As Ian Lyngen, head of U.S. rates strategy at BMO Capital Markets, put it: "The market is now left to ponder whether the renewed attacks are simply an iteration of the negotiations or if Trump has abandoned the peace talks for the foreseeable future. The weightier risk is that the conflict's timeline has been effectively reset and investors are facing months of uncertainty for the global outlook yet again".

Daniela Hathorn, senior market analyst at Capital.com, noted that "renewed tensions in the Middle East have interrupted what had become an increasingly complacent market narrative, prompting investors to reassess geopolitical risks after several weeks of pricing in a smooth path toward de-escalation".

---

### The Dominoes Fall: Who Got Hit Hardest

The selloff was broad, but some sectors felt the pain more than others.

#### The Losers

- **Airlines and cruise lines:** Companies with big fuel bills were among the hardest hit. American Airlines lost 5.9%, United Airlines fell 4.9%, and Norwegian Cruise Line Holdings dropped 3.1%.

- **Homebuilders and housing-related stocks:** Rising Treasury yields—driven by inflation fears—threaten to push mortgage rates higher. Builders FirstSource fell 6.6%, PulteGroup dropped 4.6%, and D.R. Horton sank 4.5%.

- **Retail and consumer discretionary:** Booking Holdings gave up 4%, Home Depot retreated 3%, and McDonald's slipped more than 1%.

- **The broad market:** Drops of 4% for Sherwin-Williams and 3.3% for Home Depot were two of the biggest reasons the Dow was heading toward its worst loss in about a month.

#### The Winners

- **Energy stocks:** Marathon Petroleum stood out with a 4% advance, while ConocoPhillips and Chevron each picked up 2%.

- **AI stocks (some):** Nvidia rose a modest 0.3%, and was the second-strongest force pushing upward on the S&P 500 because it's the largest stock on Wall Street. The strongest push upward on the market came from Broadcom, which rose 4.1% after Apple announced a multiyear commitment with Broadcom to design and produce custom components for its products.

- **Semiconductors (eventually):** After selling off a day earlier, semiconductor shares found their footing; the VanEck Semiconductor ETF ticked up 0.6%, though the fund has yet to recover much ground and sits roughly 12% beneath its recent peak.

---

### The Fed Factor: Why Wednesday's Selloff Could Get Worse

If geopolitics weren't enough, investors also had to digest the minutes from the Federal Reserve's June meeting—the first under new Chair Kevin Warsh.

**The context:** Warsh has already signaled a more hawkish stance than his predecessor. The minutes were expected to clarify how policymakers are thinking about potential rate increases given lingering inflation concerns.

**The inflation risk:** The oil price surge is a direct threat to the Fed's inflation outlook. With Brent crude jumping 8% in a single day, the inflation fears that had been easing are now back with a vengeance. Oil prices that had been falling, and boosting arguments that inflation would decline, began rising again after the U.S. and Iran traded strikes and Trump declared the framework for a peace deal had been scrapped.

**The bond market reaction:** Treasury yields rose with the price of oil. The yield on the 10-year Treasury climbed to 4.59% from 4.55% late Tuesday and from just 3.97% before the war with Iran began. The U.K.'s 10-year Gilt yielded 4.923%, up 7 basis points on the day.

Higher yields mean higher borrowing costs for companies and consumers, which could slow economic growth and further pressure stock valuations. As one analyst noted, "higher rates can keep a lid on inflation, but they also slow the economy and hurt prices for all kinds of investments".

---

### Global Contagion: It Wasn't Just America

The U.S. selloff was part of a global wave of risk aversion.

**Europe:** Losses for European markets accelerated after Trump made his comments, with Germany's DAX losing 2.2%.

**Asia:** South Korea's Kospi dropped 5.3% and continued its sharp swings amid dueling worries and euphoria about AI stocks.

**The common thread:** Everywhere, investors were fleeing risk assets and seeking safety in oil and bonds. The geopolitical risk premium that had been priced out of global markets over the past three weeks is now being priced back in.

---

### Frequently Asked Questions

**Q: Why did the Dow drop nearly 800 points on July 8, 2026?**

A: President Trump declared the U.S.-Iran ceasefire "over" at the NATO summit in Ankara, signaling that the war would escalate. Oil prices surged more than 8%, reigniting inflation fears and prompting a broad-based selloff across risk assets.

**Q: What happened to the U.S.-Iran ceasefire?**

A: The truce had been fragile for weeks. After the U.S. struck Iran in response to attacks on commercial vessels in the Strait of Hormuz, Trump declared the memorandum of understanding "over" and said the U.S. would strike again.

**Q: How much did oil prices rise?**

A: Brent crude surged 8% to $80.09 a barrel, while WTI jumped 7.6% to trade at $75.77.

**Q: Why didn't the market fall even more?**

A: Several traders noted that neither side wants to prolong the war. JPMorgan's trading desk said "the situation has not materially changed with neither US / Iran showing a desire for an extended conflict". Trump also said negotiations to end the war can continue.

**Q: What does this mean for the Federal Reserve?**

A: The oil price surge threatens to reignite inflation, which could force the Fed to raise interest rates. The minutes from the Fed's June meeting—the first under new Chair Kevin Warsh—were released Wednesday afternoon.

**Q: Is this the beginning of a broader market correction?**

A: It's too early to say. As Ian Lyngen of BMO Capital Markets noted, the key question is whether the renewed attacks are "simply an iteration of the negotiations or if Trump has abandoned the peace talks for the foreseeable future". If the former, this could be an interlude; if the latter, investors face "months of uncertainty for the global outlook yet again".

**Q: What should investors watch for next?**

A: Key developments to monitor include: further military escalation between the U.S. and Iran, the status of negotiations to end the conflict, the June CPI report scheduled for July 14, and any signals from the Federal Reserve about interest rate policy.

---

### Conclusion: The Geopolitical Risk Premium Is Back

Three weeks. That's how long the peace dividend lasted.

On June 17, the U.S. and Iran signed a memorandum of understanding that seemed to promise a path to de-escalation. Oil prices plunged. Stock markets rallied. Investors breathed a sigh of relief.

On July 8, that relief evaporated. Trump declared the ceasefire "over," oil surged 8%, and the Dow plunged nearly 800 points. The geopolitical risk premium that had been priced out of global markets is now being priced back in.

**Here's what we know for certain:**

**The conflict is escalating.** Trump has signaled he intends to strike Iran again, and Iran has shown it can disrupt the Strait of Hormuz. The 60-day negotiation window that was supposed to lead to a permanent truce is now effectively closed.

**Oil prices are heading higher.** The 8% surge on Wednesday is likely just the beginning. If the Strait of Hormuz is blocked again, oil could easily return to the $100+ levels seen during the peak of the conflict.

**Inflation is back.** The oil price spike threatens to undo months of progress on inflation. That means the Fed is likely to remain hawkish—and rate cuts are off the table.

**Volatility is the new normal.** The market's whiplash response to the ceasefire collapse is a reminder that geopolitical risk can't be ignored. The peace dividend was real—but it was also fragile.

As Daniela Hathorn of Capital.com put it: "The latest attacks have reminded investors that while a ceasefire remains in place, a lasting agreement between the U.S. and Iran is far from guaranteed. Markets had become comfortable with the idea that the conflict would gradually fade into the background but recent developments suggest that assumption may have been premature".

For investors, the message is clear: **prepare for more volatility.** The ceasefire is over. The war is not. And the market is just beginning to price in the uncertainty.

---

### Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, geopolitical developments, and economic data are subject to rapid change. Past performance is not indicative of future results. You should consult with a qualified financial advisor before making any investment decisions.

---

*Published: July 8, 2026*

--Read more-

**Tags:** Dow Jones, stock market today, US Iran ceasefire, oil prices, geopolitical risk, NATO summit, Federal Reserve, Kevin Warsh, Fed minutes, inflation, market selloff, Middle East conflict, energy stocks, airlines, homebuilders, AI stocks, Broadcom, Nvidia, market volatility, Trump Iran, Strait of Hormuz, Brent crude, WTI crude

Stock Market Today: Dow Dives As U.S.-Iran Ceasefire Falls Apart; Arista Bucks Sell-Off

## The ceasefire that was supposed to bring stability to oil markets and calm geopolitical tensions has collapsed. Investors are fleeing risk, oil is surging, and the Dow is paying the price—but one AI networking stock is quietly staging a rally.

### Introduction: The "Peace Dividend" Evaporates

Just three weeks ago, the world breathed a collective sigh of relief. On June 17, 2026, the U.S. and Iran signed a memorandum of understanding, bringing a fragile ceasefire to a war that had sent oil prices soaring past $120 a barrel and threatened to destabilize the global economy. Investors celebrated. Oil prices plunged back to prewar levels. The stock market rallied.

That peace dividend lasted exactly 21 days.

The Dow Jones Industrial Average plunged nearly **800 points**. Oil surged more than 7%. And the geopolitical risk premium that investors had so eagerly discounted just weeks ago came roaring back.

### The Numbers That Matter: A Market in Panic

Let's start with the damage. As of late Wednesday trading:

|-------|-------|--------|----------|

| **Dow Jones** | ~52,126 | **-798 points** | **-1.51%** |

| **S&P 500** | ~7,443 | **-60 points** | **-0.81%** |

| **Nasdaq** | ~25,649 | **-169 points** | **-0.66%** |

| **Oil (Brent)** | ~$79.65/bbl | **+7.5%** | — |

| **Oil (WTI)** | ~$75.41/bbl | **+7.1%** | — |

The Dow's nearly 800-point drop was the index's worst single-day performance in weeks. Losses were broad-based across all major indexes, with the Nasdaq Composite off 0.6% and the S&P 500 down 0.7%.

**The oil market told an even more dramatic story.** Brent crude surged more than 7% to settle at $79.65 a barrel, while West Texas Intermediate jumped 7.1% to $75.41. The spike erased weeks of price declines driven by the ceasefire optimism. Just days earlier, oil had returned to prewar levels—around $72 a barrel. Now, that progress is gone.

### The Ceasefire Collapse: What Happened?

The collapse didn't happen overnight—but it happened fast.

**The backstory:** On June 17, the U.S. and Iran signed a memorandum of understanding aimed at ending the conflict. The agreement included provisions for Iran to resume oil exports, the reopening of the Strait of Hormuz, and a 60-day negotiation window toward a permanent truce. Investors treated the deal as a geopolitical breakthrough.

**The trigger:** Trump's remarks followed U.S. strikes against Iran on Tuesday, carried out in response to attacks on three commercial vessels in the Strait of Hormuz. Iran had targeted sites in Bahrain and Kuwait, and the U.S. responded forcefully.

Analysts noted that Trump's remarks represented the "most serious break" in the ceasefire since the memorandum was signed. The market had treated the June agreement as a durable framework for de-escalation. That optimism now looks "fragile".

### The Dominoes Fall: Who Got Hit Hardest

The selloff was broad, but some sectors felt the pain more than others.

**The Losers:**

- **Airlines and cruise lines:** Companies with big fuel bills were among the hardest hit. American Airlines lost 3.4%, and Norwegian Cruise Line Holdings fell 2.4%. Delta, United, Southwest, and American all slipped as oil prices surged.

- **Homebuilders and housing-related stocks:** Rising Treasury yields—driven by inflation fears—threaten to push mortgage rates higher. Builders FirstSource fell 5.2%, PulteGroup dropped 3.8%, and D.R. Horton sank 3.6%.

- **Retail and consumer discretionary:** Booking Holdings gave up 4%, Home Depot retreated 3%, and McDonald's slipped more than 1%.

- **Tech megacaps:** The "Magnificent Seven" stocks collectively moved lower, with Meta leading the declines.

- **Semiconductors initially:** Chip stocks were hit hard early in the session. Micron and SanDisk both fell more than 4% in premarket trading.

**The Winners:**

- **Energy stocks:** Marathon Petroleum advanced 4%, while ConocoPhillips and Chevron each picked up 2%.

- **Chipmakers (eventually):** After selling off a day earlier, semiconductor shares found their footing. The VanEck Semiconductor ETF ticked up 0.6%, though the fund remains roughly 12% below its recent peak. The Philadelphia Semiconductor Index staged a rebound, rising 0.9%.

The broader message is clear: when geopolitical risk spikes, the market punishes companies that depend on cheap energy and stable consumer spending, while rewarding those that benefit from higher oil prices or have pricing power.

### The Bright Spot: Arista Networks Bucks the Trend

In a day dominated by red ink, one stock stood out.

**Arista Networks (ANET) surged more than 5%** on Wednesday, with shares reaching $174.92. The rally was driven by a combination of fundamental strength and a major institutional endorsement.

**The catalyst:** ClearBridge Large Cap Growth Strategy revealed in its latest quarterly report that it had "scaled up" its position in Arista Networks during the second quarter. The fund cited Arista's leadership in AI infrastructure as a key reason for the move, noting that it sees "excess return opportunities" in the second half of the year.

**The fundamentals:** Arista's Q1 2026 earnings provided solid support. The company reported revenue of $2.709 billion, up 35.13% year-over-year, with net profit of $1.023 billion, up 25.69%. The company is a key player in the $1.8 trillion AI infrastructure space.

**The product pipeline:** Arista recently introduced its 1.6T network platform 7060XE7, targeting rack-scale AI data centers and high-density Ethernet AI fabric markets. As cloud providers and hyperscalers continue to build out AI infrastructure, Arista is positioned to benefit from the growing demand for high-performance networking equipment.

**The takeaway:** In a market defined by geopolitical panic, Arista's rally is a reminder that the AI infrastructure trade is far from dead. While energy stocks may be the short-term winners from higher oil prices, companies that enable the AI buildout continue to attract long-term capital.

### The Fed Factor: Why Wednesday's Selloff Could Get Worse

If geopolitics weren't enough, investors also had to digest the minutes from the Federal Reserve's June meeting—the first under new Chair Kevin Warsh.

**The context:** Warsh has already signaled a more hawkish stance than his predecessor. In June, he shortened the Fed's policy statement and declined to participate in interest rate path projections. The minutes were expected to clarify how policymakers are thinking about potential rate increases given lingering inflation concerns.

**The inflation risk:** The oil price surge is a direct threat to the Fed's inflation outlook. With Brent crude jumping 7.5% in a single day, the inflation fears that had been easing are now back with a vengeance. As one analyst put it, the Fed minutes are expected to "reawaken the hawkish sentiment that had diminished somewhat," as they will reflect officials' hawkish "dot plot" forecasts.

**The market pricing:** Currency markets have already fully priced in a Fed rate hike for October. If the minutes reinforce that expectation, Wednesday's selloff could be just the beginning.

**The bond market reaction:** Treasury yields rose with the price of oil. The yield on the 10-year Treasury rose to 4.58% from 4.55% late Tuesday—and from just 3.97% before the war with Iran began. Higher yields mean higher borrowing costs for companies and consumers, which could slow economic growth and further pressure stock valuations.

### Global Contagion: It Wasn't Just America

The U.S. selloff was part of a global wave of risk aversion.

**Europe:** The pan-European Stoxx 600 fell 0.7%. Germany's DAX lost 1.6%, while the UK's FTSE 100 dropped 1.44% and France's CAC 40 fell 2.09%.

**Asia:** South Korea's Kospi dropped 5.3%, continuing its sharp swings amid dueling worries and euphoria about the AI trade. Asian stocks were poised for a second day of declines.

### Frequently Asked Questions

**Q: Why did the Dow drop nearly 800 points on July 8, 2026?**

A: President Trump declared the U.S.-Iran ceasefire "over" at the NATO summit in Ankara, signaling that the war would escalate. Oil prices surged more than 7%, reigniting inflation fears and prompting a broad-based selloff across risk assets.

**Q: What happened to the U.S.-Iran ceasefire?**

**Q: How much did oil prices rise?**

A: Brent crude surged 7.5% to $79.65 a barrel, while WTI jumped 7.1% to $75.41.

**Q: Why did Arista Networks rise while the market fell?**

A: Arista gained more than 5% after ClearBridge Large Cap Growth Strategy disclosed it had increased its position in the company. The fund cited Arista's leadership in AI infrastructure as a key reason for the move.

**Q: What does this mean for the Federal Reserve?**

A: The oil price surge threatens to reignite inflation, which could force the Fed to raise interest rates. Markets have already fully priced in a rate hike for October. The Fed minutes released Wednesday were expected to confirm a hawkish tilt.

**Q: Is this the beginning of a broader market correction?**

A: It's too early to say. The selloff was driven by geopolitical panic, not deteriorating fundamentals. However, with oil prices rising, inflation fears returning, and the Fed signaling higher rates, the risk of further declines is real. As one analyst noted, negative news is stacking up, and there's a lack of major positive catalysts in the near term to reverse the trend.

### Conclusion: The Geopolitical Risk Premium Is Back

Three weeks. That's how long the peace dividend lasted.

On June 17, the U.S. and Iran signed a memorandum of understanding that seemed to promise a path to de-escalation. Oil prices plunged. Stock markets rallied. Investors breathed a sigh of relief.

On July 8, that relief evaporated. Trump declared the ceasefire "over," oil surged 7%, and the Dow plunged nearly 800 points. The geopolitical risk premium that had been priced out of global markets is now being priced back in—with interest.

**Here's what we know for certain:**

**Oil prices are heading higher.** The 7% surge on Wednesday is likely just the beginning. If the Strait of Hormuz is blocked again, oil could easily return to the $100+ levels seen during the peak of the conflict.

**Inflation is back.** The oil price spike threatens to undo months of progress on inflation. That means the Fed is likely to remain hawkish—and rate cuts are off the table.

**The AI trade is still alive.** Arista's 5% rally in a down market is a reminder that the AI infrastructure buildout continues regardless of geopolitical turmoil. Investors are still willing to pay for exposure to the AI megatrend—they're just being more selective about where they put their money.

For investors, the message is clear: **prepare for more volatility.** The ceasefire is over. The war is not. And the market is just beginning to price in the uncertainty.

---

### Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, geopolitical developments, and economic data are subject to rapid change. Past performance is not indicative of future results. You should consult with a qualified financial advisor before making any investment decisions.

---

*Published: July 8, 2026*

-Read more--

**Tags:** Dow Jones, stock market today, US Iran ceasefire, oil prices, geopolitical risk, Arista Networks, ANET stock, Federal Reserve, inflation, market selloff, Middle East conflict, NATO summit, Kevin Warsh, Fed minutes, AI infrastructure, semiconductor stocks, energy stocks, travel stocks, market volatility

Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal

**A 102% premium, a $10 billion price tag, and a resurgent M&A market have put this obesity-focused biotech in the crosshairs of Big Pharma.**

---

## Introduction: The Deal That Changed the Game

On July 6, 2026, Vertex Pharmaceuticals dropped a bombshell on the biotech industry. The company agreed to acquire Crinetics Pharmaceuticals for **$85 per share in cash**—a **102% premium** to Crinetics' previous closing price. The deal valued Crinetics at approximately **$10 billion** in total equity value, or about **$8.8 billion net of cash acquired**.

The transaction, unanimously approved by both companies' boards, is expected to close in the third quarter of 2026.

For the biotech industry, the message was unmistakable: **Big Pharma is still willing to pay up for the right assets.** And for investors in Viking Therapeutics (VKTX), the deal sent a powerful signal that their company might be next.

---

## The Spark: What Vertex's Crinetics Deal Means for the M&A Landscape

### A 102% Premium Sets the Bar

Vertex's offer wasn't just generous—it was transformative. The $85-per-share cash bid represented more than double Crinetics' market value before the deal was announced. It demonstrated that Vertex was willing to pay a significant premium to acquire Crinetics' lead asset, **PALSONIFY (paltusotine)** , the first once-daily oral treatment for adults with acromegaly, approved by the FDA in September 2025.

Vertex plans to finance the deal using cash on hand and debt, supported by **$4.5 billion of committed bridge financing** from Bank of America and Morgan Stanley. The company expects the acquisition to become accretive to adjusted operating income in 2029.

### The Fourth $10 Billion Deal of 2026

The Vertex-Crinetics deal is the **fourth biotech acquisition of $10 billion or more** in 2026, following Sun Pharma's $11.75 billion acquisition of Organon, AbbVie's $10.9 billion acquisition of Apogee, and GSK's $10.6 billion acquisition of Nuvalent.

This wave of megadeals signals that large pharmaceutical companies are aggressively seeking to bolster their pipelines—and they're willing to pay top dollar for de-risked, late-stage assets.

### Why This Matters for Viking

For Viking Therapeutics, the timing couldn't be better. The company sits at the **intersection of obesity and metabolic drug development**—an area that has attracted massive capital commitments from major biopharma companies. With both injectable and oral versions of its lead candidate VK2735 advancing, Viking operates in a part of the market where larger players are actively seeking assets.

As one analyst put it, "Vertex's $10B Crinetics buy has revived mid-cap biotech M&A speculation, putting VKTX and BCRX back in focus".

---

## Why Viking Therapeutics Is in the Spotlight

### The Crown Jewel: VK2735

Viking's lead candidate, **VK2735**, is a dual GLP-1/GIP receptor agonist being developed in both injectable and oral formulations for obesity. The drug has already produced compelling data:

- **Oral VK2735**: Achieved up to **12.2% weight loss** after 13 weeks in a Phase 2 study, with **80% of participants achieving at least 10% weight loss**.

- **Injectable VK2735**: Demonstrated up to **14.7% weight loss** after 13 weeks in earlier Phase 2 data.

- **No plateau observed**: Importantly, weight loss continued through the end of the trial period, suggesting the drug's full potential may be even greater.

The company is now advancing the subcutaneous version of VK2735 in the **Phase 3 VANQUISH program**, with two pivotal trials—VANQUISH-1 and VANQUISH-2—already fully enrolled. VANQUISH-1 alone includes over **4,500 patients**.

### The Oral Advantage

While the obesity drug market is currently dominated by Novo Nordisk and Eli Lilly with injectable drugs, both companies have recently won FDA approval for oral obesity pills as well. Viking's dual-track approach—developing both injectable and oral formulations—could offer **flexibility for patients who prefer to start with or switch to a pill**.

### The Maintenance Catalyst

The most important near-term catalyst for Viking is **Q3 2026 maintenance data** from a 180-patient study testing different long-term dosing regimens. The study enrolls obese volunteers who first receive weekly subcutaneous VK2735 for 19 weeks to drive initial weight loss, then switches them to flexible maintenance regimens—**monthly subcutaneous injections, daily oral tablets, weekly oral tablets, or placebo**.

**Why this matters:** Obesity drugs face major challenges with long-term adherence and weight regain. Positive maintenance data could strongly differentiate Viking's program from competitors by demonstrating that VK2735 can sustain weight loss with far less frequent dosing.

### The Pipeline Beyond VK2735

Viking isn't a one-drug company. The company recently initiated a **Phase 1 trial of VK3019**, a novel amylin receptor agonist for obesity. This adds another potential lever for future interest, beyond its flagship obesity programs.

The company's pipeline also includes VK2809, in mid-stage study for non-alcoholic steatohepatitis (NASH), and VK0214, in early-stage study for X-linked adrenoleukodystrophy (X-ALD).

---

## The Financial Picture: Cash, Burn, and Valuation

### Cash Runway

Viking ended Q1 2026 with roughly **$603 million in cash and investments**, which management believes should fund operations into 2028. This provides the company with significant financial flexibility to advance its pipeline without immediate pressure to raise capital.

### The Burn Rate

However, Viking is still a clinical-stage company with **no approved products** and accelerating cash burn. The Q4 2025 net loss hit **$157.66 million**, and the Q1 2026 net loss was $158.3 million, worsening from $45.6 million year-over-year. This sharpens the strategic clock for the company to either bring a product to market or find a partner—or a buyer.

### Market Cap and Analyst Targets

As of July 7, 2026, Viking's stock traded at **$42.13**, up 8.83% on the day. The company has a market cap near **$3.59 billion**.

**Wall Street is overwhelmingly bullish:**

| Metric | Value |

|--------|-------|

| **Average 12-Month Target** | $92.58 (120% upside) |

| **Analyst Ratings** | 5 Strong Buy, 13 Buy, 2 Hold, 0 Sell |

| **Overall Rating** | Strong Buy |

| **Piper Sandler Price Target** | $71 (69% upside) |

The gap between the current price and analyst targets reflects the significant upside potential if VK2735's clinical data continues to deliver.

---

## The Takeover Probability: What the Market Is Pricing In

### 38.5% Implied Probability

Polymarket traders are watching Viking more closely than any other biotech for an acquisition. The company carries a **38.5% implied probability of being acquired before 2027**, with all-time volume above $1.68 million on that single contract.

### Why Viking Is the Most-Watched M&A Target

Several factors make Viking an attractive acquisition candidate:

1. **Late-stage obesity asset**: VK2735 is arguably the most advanced obesity asset not yet owned by Big Pharma.

2. **Dual formulation strategy**: Both injectable and oral versions provide flexibility for patients and commercial positioning.

3. **Large addressable market**: The obesity market is expected to eventually generate well over **$100 billion annually**.

4. **Big Pharma's desperation**: Large pharmaceutical companies are desperate to secure obesity drug exposure, and Viking controls one of the more advanced independent GLP-1/GIP programs still available.

5. **Cash runway**: With $603 million in cash, Viking has the financial resources to negotiate from a position of strength.

### Potential Suitors

The most obvious potential acquirers are the companies already dominating the obesity market:

- **Eli Lilly (LLY)**: The American rival to Novo Nordisk would benefit from adding Viking's pipeline to its existing obesity portfolio.

- **Novo Nordisk**: The Danish drugmaker could acquire Viking to defend its market leadership.

- **Other Big Pharma players**: Pfizer, Merck, and others have all expressed interest in entering or expanding in the obesity market.

---

## The Human Element: What This Means for Investors

### For Current Shareholders

If you own VKTX stock, the Vertex-Crinetics deal is a validation of the thesis that Big Pharma is willing to pay premium prices for quality biotech assets. The 102% premium Vertex paid for Crinetics sets a benchmark for what a potential Viking acquisition could look like.

**The key question:** Will Viking be acquired, and at what price? Analyst targets of $92.58 imply a 120% upside from current levels. A buyout at a similar premium to Crinetics could be even higher.

### For Prospective Investors

The risk-reward calculation for Viking is straightforward:

- **Upside**: Positive Q3 maintenance data could push the stock significantly higher. A buyout at a premium would deliver substantial returns.

- **Downside**: Clinical trial failures or disappointing data could send the stock tumbling. Viking is still a clinical-stage company with no approved products.

**The prudent approach**: Consider your risk tolerance and position size. The 38.5% implied acquisition probability suggests the market sees a real chance of a deal, but it's far from guaranteed.

### The Human Emotions Behind the Headlines

- **The Viking shareholder**: You've watched the stock rally on buyout speculation. You're hopeful but cautious—you've seen biotech stocks soar and crash on clinical data before.

- **The Big Pharma executive**: You're watching Viking's Q3 maintenance data closely. If it's positive, you know you'll be in a bidding war with competitors.

- **The biotech analyst**: You've been covering Viking for years. You know the company has one of the best obesity assets in the pipeline. You're waiting for the data to confirm your thesis.

- **The retail trader**: You bought VKTX on the Vertex-Crinetics news. You're riding the momentum, but you know the next catalyst is the real test.

---

## Frequently Asked Questions

### Q: What did Vertex pay for Crinetics?

A: Vertex agreed to acquire Crinetics for **$85 per share in cash**, representing a **102% premium** to Crinetics' previous closing price. The deal values Crinetics at approximately **$10 billion** in total equity value, or about **$8.8 billion net of cash acquired**.

### Q: Why does the Vertex-Crinetics deal matter for Viking?

A: The deal signals that Big Pharma is willing to pay significant premiums for quality biotech assets. It has revived mid-cap biotech M&A speculation, putting Viking's obesity pipeline in the spotlight.

### Q: What is Viking's lead drug candidate?

A: Viking's lead candidate is **VK2735**, a dual GLP-1/GIP receptor agonist being developed in both injectable and oral formulations for obesity. It has demonstrated up to 14.7% weight loss in Phase 2 studies.

### Q: When will Viking release key data?

A: The most important near-term catalyst is **Q3 2026 maintenance data** from a study testing different long-term dosing regimens for VK2735. Following that, Viking plans to initiate pivotal late-stage trials for the oral tablet formulation in the second half of 2026.

### Q: What is Viking's cash position?

A: Viking ended Q1 2026 with roughly **$603 million in cash and investments**, which management believes should fund operations into 2028.

### Q: What is the probability of Viking being acquired?

A: Polymarket traders have priced in a **38.5% implied probability** of Viking being acquired before 2027.

### Q: Who might acquire Viking?

A: Potential acquirers include **Eli Lilly, Novo Nordisk, Pfizer, Merck**, and other large pharmaceutical companies seeking exposure to the obesity market.

### Q: What do analysts say about Viking?

A: Wall Street is overwhelmingly bullish. The average 12-month price target is **$92.58**, implying **120% upside** from current levels. The stock has 5 "Strong Buy," 13 "Buy," and 2 "Hold" ratings, with no "Sell" ratings.

---

## Conclusion: A Pivotal Moment for Viking Therapeutics

The Vertex-Crinetics deal has sent a clear signal to the biotech industry: **Big Pharma is still willing to pay up for the right assets.** For Viking Therapeutics, that signal couldn't come at a better time.

With one of the most advanced independent obesity pipelines in biotech, a dual injectable-oral strategy, and compelling clinical data, Viking is positioned at the center of the M&A spotlight. The Q3 maintenance data could be the catalyst that either validates the company's thesis or exposes its vulnerabilities.

**Here's what we know for certain:**

**The market is watching.** Vertex's $10 billion, 102%-premium deal has revived mid-cap biotech M&A speculation, and Viking is one of the most closely watched targets.

**The asset is compelling.** VK2735 has demonstrated up to 14.7% weight loss in Phase 2 studies, with both injectable and oral formulations advancing through late-stage development.

**The catalysts are coming.** Q3 maintenance data, oral VK2735 Phase 3 initiation, and VK3019 early-stage data are all expected in the coming months.

**The valuation gap is significant.** With analyst targets implying 120% upside and a 38.5% implied acquisition probability, the market is pricing in substantial potential.

For investors, the question isn't whether Viking is a compelling opportunity—it's whether the data will deliver. As one analyst put it, Viking's Q3 maintenance data is an **"underappreciated" catalyst** that could strongly differentiate the company's program from competitors.

The next few months will be pivotal. And for Viking Therapeutics, the stakes couldn't be higher.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Clinical trial outcomes, M&A speculation, and market conditions are subject to rapid change. Past performance is not indicative of future results. You should consult with a qualified financial advisor before making any investment decisions.

---

*Published: July 8, 2026*

welcome my visitors

Welcome to Our moon light Hello and welcome to our corner of the internet! We're so glad you’re here. This blog is more than just a collection of posts—it’s a space for inspiration, learning, and connection. Whether you're here to explore new ideas, find practical tips, or simply enjoy a good read, we’ve got something for everyone. Here’s what you can expect from us: - **Engaging Content**: Thoughtfully crafted articles on [topics relevant to your blog]. - **Useful Tips**: Practical advice and insights to make your life a little easier. - **Community Connection**: A chance to engage, share your thoughts, and be part of our growing community. We believe in creating a welcoming and inclusive environment, so feel free to dive in, leave a comment, or share your thoughts. After all, the best conversations happen when we connect and learn from each other. Thank you for visiting—we hope you’ll stay a while and come back often! Happy reading, sharl/ moon light

moonlight

9.7.26

Meet SK Hynix, the Trillion-Dollar South Korean Chipmaker Debuting on U.S. Markets

Nasdaq Rises as Chip Stocks Rebound and Trump Flips the Script on Iran

8.7.26

U.S. Stocks Fall After Trump Says Iran Ceasefire Is Over for Him

Stock Market Today: Dow Dives As U.S.-Iran Ceasefire Falls Apart; Arista Bucks Sell-Off

Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal

science

science

wether & geology

occations

politics news

media

technology

media

sports

art , celebrities

news

health , beauty

business

Featured Post

StubHub Fails to Turn Profit as Costs Outpace Revenue Growth

Wikipedia

Contact Form

Translate

My Blog

Total Pageviews

Popular Posts

welcome my visitors

Pages

labekes

Followers

Blog Archive

Search This Blog

moonlight

moon light

Followers

9.7.26

8.7.26

science

science

wether & geology

occations

politics news

media

technology

media

sports

art , celebrities

news

health , beauty

business

Featured Post

Wikipedia

Contact Form

Translate

Subscribe To moonlight

My Blog

Total Pageviews

Popular Posts

welcome my visitors

Pages

labekes

Followers

Blog Archive

Search This Blog